Novartis (NVS) Tops Q1 EPS by 13c, raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St turns lower as crude spikes, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
Novartis (NVS) PT Raised to $108 at CFRA
April 23, 2024 1:11 PM EDTCFRA analyst Wan Nurhayati raised the price target on Novartis (NYSE: NVS) to $108.00 (from $105.00) while maintaining a Hold rating.
The analyst comments "We raise our target price by $3 to $108, implying a 2024 P/E of 15.4x, largely in line with the peer average. Novartis... More



